Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEAPORT 1: INZ-701 in End-Stage Kidney Disease Undergoing Hemodialysis
NCT06283589Phase 1Completed
- Sponsor
- Inozyme Pharma
- Start
- Feb 2024
- Primary completion
- Jul 2024
- Modality
- Replacement Enzymes, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of INZ-701 in calciphylaxis (CUA) and end-stage kidney disease (ESKD), sponsored by Inozyme Pharma. Primary endpoint: Change From Baseline in Plasma Inorganic Pyrophosphate (PPi) Concentrations at 12 months. Started Feb 2024; status: completed.
02
Drugs
INZ-701
03
Conditions
calciphylaxis (CUA)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on NCT06283589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06283589.